Alternative Data for Spruce Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 45 | Sign up | Sign up | Sign up |
| Facebook Followers | 350 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,988 | Sign up | Sign up | Sign up |
| X Followers | 457 | Sign up | Sign up | Sign up |
| X Mentions | 16 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 25 | Sign up | Sign up | Sign up |
About Spruce Biosciences
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B.
| Price | $59.90 |
| Target Price | Sign up |
| Volume | 41,350 |
| Year Range | $5.25 - $182.6 |
| Analyst Rating | 33% buy |
| Industry | Biotechnology |
In the news
HC Wainwright & Co. Maintains Buy on Spruce Biosciences, Lowers Price Target to $200February 18 - Benzinga |
|
Spruce Biosciences Completes Type B Meetings With FDA Regarding Its Upcoming Biologics License Application Submission For Tralesinidase Alfa Enzyme Replacement Therapy, Application Submission Now Anticipated In Q4 For Sanfilippo Syndrome Type BFebruary 17 - Benzinga |
|
 |
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic CollaborationJanuary 18 - Yahoo |
|
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue CapitalJanuary 7 - Yahoo |
Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline ValueMarch 12 - GlobeNewswire |
|
Insider Transactions View All
| Parkman Healthcare Partners LLC filed to sell 1,050 shares at $17.5. October 8 '25 |
| Parkman Healthcare Partners LLC filed to sell 1,050 shares at $17.5. October 15 '25 |
| Parkman Healthcare Partners LLC filed to sell 1,075 shares at $19.3. October 8 '25 |
| Parkman Healthcare Partners LLC filed to buy 1,307 shares at $17.9. October 8 '25 |
| Parkman Healthcare Partners LLC filed to sell 1,075 shares at $19.3. October 15 '25 |
Similar companies
Read more about Spruce Biosciences (SPRB) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Spruce Biosciences
Currently, the price of one share of Spruce Biosciences stock is $59.90.
The SPRB stock price chart above provides a comprehensive visual representation of Spruce Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Spruce Biosciences shares. Our platform offers an up-to-date SPRB stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Spruce Biosciences (SPRB) does not offer dividends to its shareholders. Investors interested in Spruce Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Spruce Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
